Does one voriconazole breakpoint suit all Candida species?

被引：6
作者：
Arendrup, Maiken Cavling
Denning, David W.
机构：
[1] Statens Serum Inst, Unit Mycol & Parasitol, DK-2300 Copenhagen, Denmark
[2] Univ Manchester, Manchester M23 9LT, Lancs, England
[3] Wythenshawe Hosp, Manchester M23 9LT, Lancs, England
来源：
JOURNAL OF CLINICAL MICROBIOLOGY | 2007年 / 45卷 / 06期
关键词：
D O I：
10.1128/JCM.00412-07
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页码：2093 / 2093
页数：1
相关论文
共 14 条
[1]   In Vivo pathogenicity of eight medically relevant Candida species in an animal model [J].
Arendrup, M ;
Horn, T ;
Frimodt-Moller, N .
INFECTION, 2002, 30 (05) :286-291
[2]   Seminational surveillance of fungemia in Denmark: Notably high rates of fungemia and numbers of isolates with reduced azole susceptibility [J].
Arendrup, MC ;
Fuursted, K ;
Gahrn-Hansen, B ;
Jensen, IM ;
Knudsen, JD ;
Lundgren, B ;
Schonheyder, HC ;
Tvede, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (09) :4434-4440
[3]   Adverse reactions to voriconazole [J].
Boyd, AE ;
Modi, S ;
Howard, SJ ;
Moore, CB ;
Keevil, BG ;
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (08) :1241-1244
[4]   Epidemiology of candidemia in Brazil:: a nationwide sentinel surveillance of candidemia in eleven medical Centers [J].
Colombo, Arnaldo L. ;
Nucci, Marcio ;
Park, Benjamin J. ;
Nouer, Simone A. ;
Arthington-Skaggs, Beth ;
da Matta, Daniel A. ;
Warnock, David ;
Morgan, Juliette .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (08) :2816-2823
[5]   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571
[6]   Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study [J].
Diekema, DJ ;
Messer, SA ;
Brueggemann, AB ;
Coffman, SL ;
Doern, GV ;
Herwaldt, LA ;
Pfaller, MA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (04) :1298-1302
[7]   Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia [J].
Krause, DS ;
Reinhardt, J ;
Vazquez, JA ;
Reboli, A ;
Goldstein, BP ;
Wible, M ;
Henkel, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2021-2024
[8]   Safety of voriconazole and dose individualization [J].
Lutsar, I ;
Hodges, MR ;
Tomaszewski, K ;
Troke, PF ;
Wood, ND .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) :1087-1088
[9]   Comparison of caspofungin and amphotericin B for invasive candidiasis. [J].
Mora-Duarte, J ;
Betts, R ;
Rotstein, C ;
Colombo, AL ;
Thompson-Moya, L ;
Smietana, J ;
Lupinacci, R ;
Sable, C ;
Kartsonis, N ;
Perfect, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :2020-2029
[10]   Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality [J].
Morrell, M ;
Fraser, VJ ;
Kollef, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3640-3645
12